33 results about "Tenascin C" patented technology

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.

The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

The invention relates to a tenascin C nucleic acid aptamer GBI-10 modified with isonucleosides or isonucleosides combined with 2'-deoxyinosine, and a preparation method and applications thereof, belonging to the field of biomedicine. In the present invention, isonucleosides or isonucleosides combined with 2'-deoxyinosine are used to replace nucleotides in different positions of tenascin C nucleic acid aptamers GBI-10, so as to change the local spatial conformation of the nucleic acid aptamers, and optimize the Its spatial structure is obtained, thereby obtaining an isonucleoside or isonucleoside combined with 2'-deoxyinosine modified tenascin C nucleic acid aptamer GBI-10. Experiments show that the tenascin C nucleic acid aptamer GBI-10 modified by this method has stronger affinity with the target protein, more specific target recognition, and higher biological activity. Therefore, it is hoped that the isonucleosides or isonucleosides combined with 2'-deoxyinosine-modified tenascin C nucleic acid aptamer GBI-10 can be prepared into anti-tumor drugs with high efficiency, high selectivity, and low toxic and side effects. It is used in tumor early detection reagents.

The present invention provides a method of determining the rheumatoid arthritis status of an individual to be tested, or the progression of rheumatoid arthritis, or an appropriate therapy for an individual suffering from rheumatoid arthritis, the method comprising the steps of: (a ) determining the level of tenascin C in a sample from said individual to be tested; and (b) comparing the level of tenascin C determined in step (a) to one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis. Figure 5 is attached when published.

Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.

The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).